| ||Format||Pages||Price|| |
|3||$41.00||  ADD TO CART|
|Hardcopy (shipping and handling)||3||$41.00||  ADD TO CART|
|Standard + Redline PDF Bundle||6||$49.20||  ADD TO CART|
This practice covers pharmaceutical process design utilizing process analytical technology, which is integral to process development as well as post-development process optimization. It is focused on practical implementation and experimental development of process understanding. The principles in this practice are applicable to both drug substance and drug product processes. For drug products, formulation development and process development are interrelated and therefore the process design will incorporate knowledge from the formulation development. The following practices and methodologies shall be done to attain desired state: risk assessment and mitigation; continuous improvement; process fitness for purpose; intrinsic performance assessment; manufacturing strategy; data collection and formal experimental design; multivariate tools; process analyzers; and process control.
This abstract is a brief summary of the referenced standard. It is informational only and not an official part of the standard; the full text of the standard itself must be referred to for its use and application. ASTM does not give any warranty express or implied or make any representation that the contents of this abstract are accurate, complete or up to date.
1.1 This practice covers process design, which is integral to process development as well as post-development process optimization. It is focused on practical implementation and experimental development of process understanding.
1.2 The term process design as used in this practice can mean:
1.2.1 The activities to design a process (the process design), or
1.2.2 The outcome of this activity (the designed process), or both.
1.3 The principles in this practice are applicable to both drug substance and drug product processes. For drug products, formulation development and process development are interrelated and therefore the process design will incorporate knowledge from the formulation development.
1.4 The principles in this practice apply during development of a new process or the improvement or redesign of an existing one, or both.
1.5 This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety and health practices and determine the applicability of regulatory limitations prior to use.
2. Referenced Documents (purchase separately) The documents listed below are referenced within the subject standard but are not provided as part of the standard.
E1325 Terminology Relating to Design of Experiments
E2475 Guide for Process Understanding Related to Pharmaceutical Manufacture and Control
E2476 Guide for Risk Assessment and Risk Control as it Impacts the Design, Development, and Operation of PAT Processes for Pharmaceutical Manufacture
E2587 Practice for Use of Control Charts in Statistical Process Control
E2629 Guide for Verification of Process Analytical Technology (PAT) Enabled Control Systems
ICS Number Code 11.120.01 (Pharmaceutics in general)
|Link to Active (This link will always route to the current Active version of the standard.)|
ASTM E2474-14, Standard Practice for Pharmaceutical Process Design Utilizing Process Analytical Technology, ASTM International, West Conshohocken, PA, 2014, www.astm.orgBack to Top